Acceptability of using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps

Evidence about the comparative effects of new treatments is typically collected in randomized controlled trials (RCTs). In some instances, RCTs are not possible, or their value is limited by an inability to capture treatment effects over the longer-term or in all relevant population subgroups. In these cases, non-randomized studies (NRS) using real-world data (RWD) are increasingly used to complement trial evidence on treatment effects for health technology assessment (HTA). However, there have been concerns over a lack of acceptability of this evidence by HTA agencies.

Source: Value in Health - February 16, 2024 Category: International Medicine & Public Health Authors: Manuel Gomes, Alex J. Turner, Cormac Sammon, Dalia Dawoud, Sreeram Ramagopalan, Alex Simpson, Uwe Siebert Tags: Policy Perspectives Source Type: research